The first quarter performance of Shiyao group: 8 innovative drugs with revenue of nearly 3 billion yuan

On May 31, medical network reported that prior to the first quarter of 2019, Sinopharm group announced its first quarter results The total revenue of the company was 5.493 billion yuan, a year-on-year increase of 25.6%; the net profit was 952 million yuan, a year-on-year increase of 28.83% During the reporting period, the revenue of innovative drugs reached 2.954 billion yuan, accounting for 53.8% of the company's revenue; the revenue of enbip increased by 32.1%, and the combination of anti-tumor drugs increased by 208%; the R & D investment increased significantly to 460 million yuan, a year-on-year increase of 77% At present, the company has about 300 varieties under research in five major new drug research fields, and the innovative drugs CD20 mAb and PI3K inhibitor are expected to be approved for listing in 2020-2021 The performance continued to grow at a high level, with a net profit of 952 million yuan On May 21, 2015, the company announced the first quarter of 2019, with an operating revenue of 5.493 billion yuan, a year-on-year increase of 25.6%; and a net profit of 952 million yuan, a year-on-year increase of 28.83% According to the report, the revenue of patent medicine business is nearly 4.245 billion yuan, an increase of 33.7% year on year; the revenue of API business is 1.249 billion yuan, an increase of 4% year on year The patent medicine business includes two parts: innovative medicine and generic medicine Driven by the core products, the revenue of innovative medicine business increased by 54.4% and that of generic medicine business increased by 2.4% API business is mainly divided into three categories: antibiotics, vitamin C and caffeine, with overall performance slowing down The results show that Shiyao group has successfully transformed from an API and generic company into a leading innovative drug company Eight innovative drugs accounted for nearly 3 billion yuan, with an increase of 208% in anti-tumor products In the first quarter, the group's innovative drug revenue was 2.954 billion yuan, accounting for 53.8% of the company's revenue According to the group's 2018 annual report, the company's revenue was 21.029 billion Hong Kong dollars, the innovative drug revenue was 10.344 billion Hong Kong dollars, accounting for 49.19% of the company's revenue With the proportion of innovative medicine business breaking through 50%, the pace of the group in the field of innovation is becoming more and more solid The innovative drugs of Sinopharm group mainly come from enbip, Ouyi, Baike and Yuanda (Dalian) At present, the innovative products are mainly divided into cardio cerebral vascular line and tumor line During the reporting period, the cardiovascular and cerebrovascular innovative drug "enbip" maintained a consistent growth trend, with a year-on-year growth of 32.1%, and the anti-tumor product portfolio increased by 208.0%, which is the fastest growing category of the company Innovative medicine products of Shiyao group the innovative medicine of Shiyao group in the field of cardio cerebral vascular include enbitup (butylphthalide soft capsule and injection), olanin (olacetam capsule and lyophilized powder injection), Xuanning (L-amlodipine maleate tablets and dispersible tablets) EBP is a national class 1 new drug, which is mainly used for the treatment of acute ischemic stroke; olanin is used for the treatment of mild to moderate vascular dementia, Alzheimer's dementia, etc.; Xuanning is mainly used for the treatment of hypertension In March 2019, Sinopharm group successfully submitted the new drug listing application of L-amlodipine maleate tablets to FDA, becoming the first pharmaceutical enterprise in China to submit NDA to FDA Amlodipine, nifedipine and left amlodipine are the main antihypertensive drugs in clinic Amlodipine is a "4 + 7" quantity purchased variety, with the price as low as 0.15 yuan / tablet According to the reference range of similar alternative varieties of selected drugs issued by Xi'an Medical Insurance Bureau, amlodipine can basically replace nifedipine (sustained-release preparation), and left amlodipine is not included in the alternative range, which shows that the product has the advantages of curative effect and differentiation The innovative drugs of Sinopharm group in the field of tumor include doxorubicin liposomes, long-term leukemic drugs (pegylated recombinant human granulocyte stimulating factor), albumin paclitaxel, imatinib, elemene, etc The three products of jinyouli, domenicol and keaili are operated separately In the first quarter, the revenue of keaili exceeded 250 million yuan, and the growth rate of domenicol and jinyouli exceeded 100% For the rapid growth of the anti-tumor sector, Shiyao group said that the company adheres to the route of academic promotion and expands its sales team, which now has about 2300 people The growth rate of R & D investment was 77%, and small and large molecule new drugs went hand in hand In the first quarter, the R & D investment of Sinopharm group increased to 460 million yuan, a year-on-year growth of 77% At present, the company has more than 300 research projects, mainly focusing on five fields of cardiovascular and cerebrovascular diseases, metabolic diseases, anti-tumor, psychoneurology and anti infection, including 30 new target macromolecular biological drugs, 40 new small molecule drugs and 55 new protochemical drugs (Class 3 or class 4 modern drugs) During the reporting period, many R & D products of Shiyao group obtained clinical licenses, including new oral anticoagulant (syha136), breast cancer drug (paclitaxel cationic liposome for injection), intrahepatic cholangiocarcinoma and urothelial cell cancer drug (syha1803) In addition, two small molecule new drugs of PetroChina group are about to go on the market, namely, L-amlodipine applied for listing in the United States and PI3K inhibitor (trade name: copiktra) applied for listing in China In September 2018, Sinopharm group obtained the exclusive license, marketing right and product approval from verastemm, an American pharmaceutical company, to develop and commercialize copiktra in China It is understood that the registration application of PI3K inhibitor of Shiyao group has been accepted and is expected to be approved for market in 2021; the production of CD20 monoclonal antibody, a new macromolecular drug, is expected to be reported in the first half of this year; the clinical phase III of the combination treatment of albumin paclitaxel and PD-1 for breast cancer is in progress Sinopharm group said it would continue to strengthen R & D investment and enrich its product pipeline in the future Innovative drug research and development will focus on cardiovascular and cerebrovascular diseases, metabolic diseases, tumors, psychoneurosis, anti infection and other fields, and through the combination of independent research and development and external M & A, cultivate heavyweight products in key fields.